Report cover image

Europe Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2032

Publisher Data Bridge Market Research
Published Oct 01, 2023
Length 192 Pages
SKU # DAABD18360490

Description

Europe Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2032


Europe duchenne muscular dystrophy treatment market is expected to reach USD 1,725,346.96 thousand by 2030 from USD 549,899.57 thousand in 2022, growing at a CAGR of 15.9% in the forecast period of 2023 to 2030.
Market Segmentation
Europe Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe) - Industry Trends and Forecast to 2030

Overview of Europe Duchenne Muscular Dystrophy Treatment Market Dynamics

Driver
• Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease

Restraint

• High treatment cost of DMD disorder

Opportunity

• Strategic initiatives by key market players

Market Players

Some of the key market players for Europe duchenne muscular dystrophy treatment market are:

• Sarepta Therapeutics, Inc.
• Solid Biosciences Inc.
• Capricor Therapeutics, Inc.
• Dyne Therapeutics
• BioMarin
• Stealth BioTherapeutics Inc
• Avidity Biosciences
• ReveraGen
• BioPharma, Inc.
• TAIHO PHARMACEUTICAL CO., LTD.
• Akashi RX
• ITALFARMACO S.p.
• NS Pharma, Inc.
• PTC Therapeutics.
• Pfizer Inc.
• FibroGen, Inc.
• SANTHERA PHARMACEUTICALS
• F. Hoffmann-La Roche Ltd

Table of Contents

192 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Europe Duchenne Muscular Dystrophy Treatment Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Treatment Type Segment Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel's Model
4.2 Porter's Five Forces Model
4.3 Pricing Analysis
5 Europe Duchenne Muscular Dystrophy Treatment Market: Regulations
5.1 Regulations In U.S.
5.2 Regulattions In Europe
5.3 Regulattions In Australia
5.4 Regulations In South Africa
5.5 Regulations In Brazil 47 
6 Market Overview
6.1 Drivers
6.1.1 Increasing Prevalence And Impact Of Duchenne Muscular Dystrophy (Dmd) Disease
6.1.2 Introduction Of Novel Therapies For Dmd Disorder
6.1.3 Rising Awareness For Dmd Treatments
6.1.4 Increase In The Number Of Clinical Trials Is A Recent Trend
6.2 Restraints
6.2.1 Limited Availability Of Dmd Treatments Due To Lack Of Advance Technology
6.2.2 High Treatment Cost Of Dmd Disorder
6.3 Opportunities
6.3.1 Development Of Healthcare Infrastructure And Increasing Investment
6.3.2 Rising Patient Inclination Towards Personalized And Effective Therapies
6.3.3 Strategic Initiatives By The Key Market Players
6.3.4 Support From Patient Advocacy Groups On The Regulatory Approval Process
6.4 Challenges
6.4.1 Lack Of Standardization In Dmd Diagnosis
6.4.2 Ethical Considerations Related To Permanent Alteration Of A Patient's Genetic Code
7 Europe Duchenne Muscular Dystrophy Treatment Market, By Treatment Type
7.1 Overview
7.2 Molecular-based Therapies
7.2.1 Antisense Oligonucleotide Therapy
7.2.1.1 Exondys 51
7.2.1.2 Amondys 45
7.2.1.3 Vyondys 53
7.3 Nonsense Mutation
7.3.1.1 Translarna
7.4 Steroid Therapy
7.4.1 Prednisone
7.4.2 Deflazacort
7.5 Others
8 Europe Duchenne Muscular Dystrophy Treatment Market, By Therapy
8.1 Overview
8.2 Exon Skipping Approach
8.2.1 Multi-exon Skipping Approach
8.2.2 Single-exon Skipping Approach
8.3 Mutation Suppression
8.4 Dystrophin-targeted Therapies
8.4.1 Gene Therapies
8.4.2 Cell Therapies
8.4.2.1 Gene Editing
8.4.2.2 Gene Addition
9 Europe Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration
9.1 Overview
9.2 Parenteral
9.3 Oral
9.4 Others
10 Europe Duchenne Muscular Dystrophy Treatment Market, By End User
10.1 Overview
10.2 Hospitals
10.3 Specialty Clinics
10.4 Homecare
10.5 Others
11 Europe Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel
11.1 Overview
11.2 Hospital Pharmacy
11.3 Retail Pharmacy
11.4 Online Pharmacy
12 Europe Duchenne Muscular Dystrophy Treatment Market, By Region
12.1 Europe
12.1.1 Germany
12.1.2 France
12.1.3 U.K.
12.1.4 Italy
12.1.5 Spain
12.1.6 Russia
12.1.7 Turkey
12.1.8 Belgium
12.1.9 Netherlands
12.1.10 Switzerland
12.1.11 Rest Of Europe
13 Europe Duchenne Muscular Dystrophy Treatment Market, Company Landscape
13.1 Company Share Analysis: Europe
14 Swot Analysis
15 Company Profiles
15.1 Sarepta Therapeutics, Inc.
15.1.1 Company Snapshot
15.1.1 Revenue Analysis
15.1.2 Company Share Analysis
15.1.3 Product Portfolio
15.1.4 Pipeline Portfolio
15.1.5 Recent Developments
15.2 F. Hoffmann-la Roche Ltd
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Company Share Analysis
15.2.4 Product Portfolio
15.2.5 Pipeline Portfolio
15.2.6 Recent Developments
15.3 Ptc Therapeutics.
15.3.1 Company Snapshot
15.3.2 Revenue Analysis
15.3.3 Company Share Analysis
15.3.4 Product Portfolio
15.3.5 Recent Development
15.4 Pfizer Inc.
15.4.1 Company Snapshot
15.4.2 Revenue Analysis
15.4.3 Company Share Analysis
15.4.4 Pipeline Portfolio
15.4.5 Product Portfolio
15.4.6 Recent Development
15.5 Akashi Rx
15.5.1 Company Snapshot
15.5.2 Pipeline Portfolio
15.5.3 Recent Developments
15.6 Avidity Biosciences
15.6.1 Company Snapshot
15.6.2 Revenue Analysis
15.6.3 Pipeline Portfolio
15.6.4 Recent Developments
15.7 Biomarin
15.7.1 Company Snapshot
15.7.2 Revenue Analysis
15.7.3 Pipeline Portfolio
15.7.4 Recent Developments
15.8 Capricor Therapeutics, Inc.
15.8.1 Company Snapshot
15.8.2 Pipeline Portfolio
15.8.3 Recent Developments
15.9 Dyne Therapeutics
15.9.1 Company Snapshot
15.9.2 Pipeline Portfolio
15.9.3 Recent Developments
15.10 Fibrogen, Inc.
15.10.1 Company Snapshot
15.10.2 Revenue Analysis
15.10.3 Pipeline Portfolio
15.10.4 Recent Development
15.11 Italfarmaco S.P.A.
15.11.1 Company Snapshot
15.11.2 Pipeline Portfolio
15.11.3 Recent Development
15.12 Ns Pharma, Inc.
15.12.1 Company Snapshot
15.12.2 Pipeline Portfolio
15.12.3 Recent Developments
15.13 Reveragen Biopharma, Inc.
15.13.1 Company Snapshot
15.13.2 Pipeline Portfolio
15.13.3 Recent Development
15.14 Santhera Pharmaceuticals
15.14.1 Company Snapshot
15.14.2 Revenue Analysis
15.14.3 Pipeline Portfolio
15.14.4 Recent Development
15.15 Taiho Pharmaceutical Co., Ltd.
15.15.1 Company Snapshot
15.15.2 Pipeline Portfolio
15.15.3 Recent Developments
15.16 Solid Biosciences Inc.
15.16.1 Company Snapshot
15.16.2 Pipeline Portfolio
15.16.3 Recent Development
15.17 Stealth Biotherapeutics Inc
15.17.1 Company Snapshot
15.17.2 Pipeline Portfolio
15.17.3 Recent Development
16 Questionnaire
17 Related Reports
List Of Tables
Table 1 List Of Prices For Approved Drugs Of The Europe Duchenne Muscular Dystrophy Treatment Market
Table 2 Europe Duchenne Muscular Dystrophy Treatment Market, By Treatment Type , 2021-2030 (Usd Thousand)
Table 3 Europe Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 4 Europe Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 5 Europe Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 6 Europe Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 7 Europe Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 8 Europe Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 9 Europe Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 10 Europe Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 11 Europe Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 12 Europe Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 13 Europe Mutation Suppression In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 14 Europe Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 15 Europe Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 16 Europe Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 17 Europe Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration , 2021-2030 (Usd Thousand)
Table 18 Europe Parenteral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 19 Europe Oral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 20 Europe Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 21 Europe Duchenne Muscular Dystrophy Treatment Market, By End Users, 2021-2030 (Usd Thousand)
Table 22 Europe Hospitals In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 23 Europe Speciality Clinics In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 24 Europe Homecare In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 25 Europe Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 26 Europe Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 27 Europe Hospital Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 28 Europe Retail Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 29 Europe Online Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 30 Europe Duchenne Muscular Dystrophy Treatment Market, By Country, 2021-2030 (Usd Thousand)
Table 31 Europe Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 32 Europe Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 33 Europe Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 34 Europe Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 35 Europe Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 36 Europe Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 37 Europe Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 38 Europe Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 39 Europe Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 40 Europe Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 41 Europe Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 42 Europe Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 43 Europe Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 44 Europe Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 45 Europe Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 46 Germany Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 47 Germany Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 48 Germany Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 49 Germany Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 50 Germany Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 51 Germany Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 52 Germany Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 53 Germany Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 54 Germany Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 55 Germany Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 56 Germany Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 57 Germany Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 58 Germany Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 59 Germany Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 60 Germany Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 61 Germany Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 62 Germany Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 63 Germany Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 64 France Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 65 France Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 66 France Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 67 France Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 68 France Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 69 France Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 70 France Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 71 France Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 72 France Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 73 France Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 74 France Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 75 France Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 76 France Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 77 France Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 78 France Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 79 France Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 80 France Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 81 France Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 82 U.K. Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 83 U.K. Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 84 U.K. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 85 U.K. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 86 U.K. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 87 U.K. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 88 U.K. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 89 U.K. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 90 U.K. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 91 U.K. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 92 U.K. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 93 U.K. Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 94 U.K. Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 95 U.K. Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 96 U.K. Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 97 U.K. Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 98 U.K. Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 99 U.K. Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 100 Italy Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 101 Italy Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 102 Italy Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 103 Italy Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 104 Italy Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 105 Italy Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 106 Italy Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 107 Italy Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 108 Italy Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 109 Italy Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 110 Italy Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 111 Italyduchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 112 Italy Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 113 Italy Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 114 Italy Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 115 Italy Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 116 Italy Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 117 Italy Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 118 Spain Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 119 Spain Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 120 Spain Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 121 Spain Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 122 Spain Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 123 Spain Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 124 Spain Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 125 Spain Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 126 Spain Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 127 Spain Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 128 Spain Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 129 Spain Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 130 Spain Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 131 Spain Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 132 Spain Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 133 Spain Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 134 Spain Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 135 Spain Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 136 Russia Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 137 Russia Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 138 Russia Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 139 Russia Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 140 Russia Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 141 Russia Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 142 Russia Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 143 Russia Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 144 Russia Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 145 Russia Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 146 Russia Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 147 Russia Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 148 Russia Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 149 Russia Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us